NYSE · Biotech stocks database
NUVB (Nuvation Bio Inc.) stock: $3.99, $1.41B market cap, $663.4M cash, $1.20B EV, $1.99B fully diluted market cap. Lead program: safusidenib (Glioma), Phase 3. Data from Fully Diluted's biotech stocks database.
On February 10, 2021, (the “Closing Date”), Nuvation Bio Inc., a Delaware corporation (“Legacy Nuvation Bio”), Panacea Acquisition Corp. (“Panacea”), and Panacea Merger Subsidiary Corp, a Delaware corporation and a direct, wholly owned subsidiary of Panacea (“Merger Sub”) consummated the transactions contemplated by an Agreement and Plan of Merger among them dated October 20, 2020 (“Merger Agreement”).
Source: 10-K FY2025 via SEC EDGAR
| Cash | $663.4M |
|---|---|
| Debt | $285.4M |
| Royalty-sale liability | $168.0M |
| Net cash | $377.9M |
| Enterprise value | $1,200.6M |
| Basic shares | 353.0M shares |
| Fully diluted shares | 498.2M shares |
| Fully diluted market cap | $1,987.7M |
| Cash per share | $1.88 |
| Quarterly burn | $43.0M |
| Cash runway | 15.4 quarters |
Cash figures as of 2026-09-30. Database snapshot: 2026-11-13.
Royalty-sale liability as of 2026-09-30 (10-Q); included in enterprise value.
Cap table as of 2026-06-30.
Loading NUVB daily closes…
Taletrectinib · Mar 16 - Apr 27 in 4 mo · Phase 1 · Healthy Adult Participants